Full-Time

Territory Manager

Confirmed live in the last 24 hours

iRhythm Technologies

iRhythm Technologies

1,001-5,000 employees

Advanced cardiac monitoring solutions provider

Biotechnology
Healthcare

Compensation Overview

$76.3k - $90kAnnually

Senior

Remote in USA

Remote work is available, but the job is focused on the northern part of New Jersey.

Category
Field Sales
Sales & Account Management
Required Skills
Sales

You match the following iRhythm Technologies's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Must have a Bachelor's degree
  • Minimum of 5 years related sales experience
  • At least 3 years in medical device sales
  • Cardiology and electrophysiology call points preferred
  • IDN experience also preferred
  • Demonstrated success developing and executing a strategic sales plan
  • History of outstanding achievements and proven sales skills
  • Strong analytical, communication, interpersonal skills
  • Very adaptive, innovative, and results driven
  • Strong work ethic and customer focus are required
  • Experience with Salesforce.com or similar sales tracking system preferred
Responsibilities
  • Prospecting, developing, and closing new business
  • Perform sales presentations to key prospects and customers
  • Consistently achieve territory sales goals and objectives
  • Build advocacy and champions within facilities
  • Enhance iRhythm’s relationship with providers and systems
  • Develop a pipeline of sales opportunities within assigned territory
  • Partner with facilities to manage existing service business
  • Utilize salesforce.com to manage all aspects of business
  • Cultivate a business plan and formulate sales strategies
  • Promote iRhythm as a leader in cardiac diagnostics and monitoring
Desired Qualifications
  • Cardiology and electrophysiology call points preferred
  • IDN experience also preferred
  • Experience with Salesforce.com or similar sales tracking system preferred

iRhythm Technologies specializes in cardiac monitoring solutions, primarily through its product, the Zio Patch. This wearable device allows for up to 14 days of continuous heart rhythm tracking, enabling healthcare providers to detect irregular heart rhythms that may not be identified during shorter monitoring periods. The Zio Patch is particularly useful for patients who suspect heart rhythm issues, as it allows them to monitor their heart activity without frequent visits to healthcare facilities, which is especially important in the context of telehealth and COVID-19. Unlike many competitors, iRhythm not only provides the monitoring device but also offers data analysis services that interpret the collected data, giving healthcare providers actionable insights. The company's goal is to enhance patient outcomes and improve healthcare workflows by making cardiac monitoring more accessible and efficient.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$102.8M

Headquarters

San Francisco, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • Expansion into European markets increases revenue and brand presence.
  • AI integration enhances diagnostic accuracy and speed for cardiac arrhythmias.
  • Growing demand for remote monitoring boosts Zio Patch's market potential.

What critics are saying

  • Increased competition from new entrants may impact iRhythm's market share.
  • Securities fraud complaint could affect investor confidence and stock prices.
  • Regulatory scrutiny may lead to higher compliance costs and operational delays.

What makes iRhythm Technologies unique

  • Zio Patch offers up to 14 days of uninterrupted cardiac monitoring.
  • iRhythm's partnership with BioIntelliSense enhances multiparameter sensor capabilities.
  • Zio Patch is the smallest and least conspicuous cardiac arrhythmia diagnostic device.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Mental Health Support

Hybrid Work Options

Pet Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Jan 13th, 2025
Irhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights And Business Update At The 43Rd Annual J.P. Morgan Healthcare Conference

iRhythmSAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.Recent Operational Highlights and Financial OutlookAnticipate full year 2024 revenue slightly above high end of previously stated guidance range of $587.5 million provided in October 2024Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accountsLaunched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024Five studies presented at the American Heart Association highlight Zio Monitor’s high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns 1Expect revenue for the full year 2025 of approximately $675 million to $685 million“This past year was a period of significant growth and transformation for iRhythm,” said Quentin Blackford, iRhythm’s President and CEO. “In our core U.S

MarketBeat
Nov 26th, 2024
Dynamic Technology Lab Private Ltd Invests $1.50 Million in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Dynamic Technology Lab Private Ltd invests $1.50 million in iRhythm Technologies, Inc. (NASDAQ:IRTC).

MPO Magazine
Oct 22nd, 2024
iRhythm Earns FDA Nod for Zio AT After Warning Letter

The letter accused iRhythm of violating Federal Food, Drug, and Cosmetic Act rules about labeling, medical device reporting, and quality systems.

Global Tech Times
Sep 20th, 2024
Kaskela Law LLC Announces Shareholder Investigation of iRhythm Technologies, Inc. (NASDAQ: IRTC) and Encourages Long-Term IRTC Shareholders to Contact the Firm

Recently a securities fraud complaint was filed against iRhythm on behalf of investors who purchased shares of the company's stock between November 5, 2021 and May 30, 2023 (the "Class Period").

TipRanks
Sep 4th, 2024
iRhythm signs exclusive license agreement with BioIntelliSense

iRhythm Technologies announced that the company has signed an exclusive license agreement with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring, ACM.